v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2026
Dec. 31, 2025
Current Assets:    
Cash $ 1,156,915 $ 251,291
Prepaid expenses and other current assets 211,969 316,583
Total Current Assets 1,368,884 567,874
Equipment and furnishings, less accumulated depreciation of $120,945 and $120,013, respectively 2,068 3,000
Operating lease right-of-use asset 102,549 126,628
Total Assets 1,473,501 697,502
Current Liabilities:    
Accounts payable 931,972 716,220
Other accrued expenses 3,159,127 3,161,379
Notes payable 92,443 217,772
Operating lease liability, current portion 49,980 48,083
Total Current Liabilities 7,707,145 6,897,378
Notes payable, non-current portion 23,621
Operating lease liability, non-current portion 53,920 79,221
Total Liabilities 7,761,065 7,000,220
Commitments and contingencies (Note 13)
Stockholders’ Deficit:    
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 420,279,879 shares issued and outstanding at June 30, 2026 and December 31, 2025 420,280 420,280
Additional paid-in capital 258,475,479 256,179,846
Accumulated other comprehensive loss (59,803) (60,191)
Accumulated deficit (265,126,832) (262,853,812)
Total Provectus Biopharmaceuticals, Inc., Stockholders’ Deficit (6,275,171) (6,298,737)
Non-controlling interest in subsidiary (12,393) (3,981)
Total Stockholders’ Deficit (6,287,564) (6,302,718)
Total Liabilities and Stockholders’ Deficit 1,473,501 697,502
Series D Convertible Preferred Stock [Member]    
Stockholders’ Deficit:    
Preferred Stock Value 957 957
Series D-1 Convertible Preferred Stock [Member]    
Stockholders’ Deficit:    
Preferred Stock Value 14,748 14,183
Nonrelated Party [Member]    
Current Liabilities:    
Accrued interest 49,469 23,540
Convertible notes payable 2,075,000 870,000
Related Party [Member]    
Current Liabilities:    
Accrued interest 114,154 120,384
Convertible notes payable $ 1,235,000 $ 1,740,000